ApicHope announced that its wholly-owned subsidiary, Guangzhou ApicHope Pharmaceutical Co., Ltd., recently received the "Drug Registration Certificate" approved and issued by the National Medical Products Administration for the Escitalopram Oxalate Drops. The indications for Escitalopram Oxalate Drops are: treatment of depression and panic disorder with or without agoraphobia. The company's approved Escitalopram Oxalate Drops are registered as a Class 3 chemical drug, considered to have passed the consistency evaluation. According to data from Minet, the sales scale of Escitalopram in public hospitals at the city and county levels in China is approximately RMB 1.88 billion in 2024